At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 40 enrolled
Drug / intervention
PL2200 Aspirin Capsules +2 moredrug
Likely dose
PL2200 Aspirin Capsules 325 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Actively Controlled, Crossover Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Patients With Type II Diabetes
In Brief
A Phase 3 clinical trial evaluating PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 40 participants across 1 site.
Detailed Summary
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as these other products, when administered to patients with diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedJan 2012
Primary CompletionJun 2012
TodayJul 2026
First PostedJan 24, 2012
Enrollment StartJan 1, 2012
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.4 years ago
Interventions
PL2200 Aspirin Capsulesdrug
325 mg aspirin; once per day for 3 days
Immediate-Release Aspirin Tabletsdrug
325 mg aspirin; once per day for 3 days
Enteric-coated aspirin capletsdrug
325 mg aspirin; once per day for 3 days